Firehawk® Gains CFDA Approval to Extend Shelf Life to Two Years
Shanghai, China - Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently gained approval from China Food and Drug Administration ("CFDA") to extend the shelf life of its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®") to two years.
The revolutionary third-generation drug-eluting stent Firehawk® is the result of eight years of research and development of MicroPort® and is the world's first and only target eluting stent ("TES"). Firehawk® was approved for market launch by the CFDA in 2014, and was approved to add 24 specifications in 2015. With its shelf life further extended, Firehawk® is expected to benefit more Chinese patients with coronary artery diseases.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.